A Phase II study of Tranzyme Pharma’s TZP-102 capsules in diabetic patients with gastroparesis has demonstrated clinically significant improvements in critical symptoms.
The study, conducted on 92 patients with diabetic gastroparesis, found that more than 50% of those on TZP-102 had normalised gastric emptying.
At the end of the once-daily, 28-day treatment period, patients on all three doses of TZP-102 showed positive results in symptom scores for nausea, early satiety, excessive fullness and postprandial fullness.
Diabetic gastroparesis is a serious disorder characterised by the inability of the stomach to empty food efficiently.
TZP-102 is an oral ghrelin agonist with potent prokinetic properties that has been developed to treat chronic gastrointestinal dysmotility disorders.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData